The emerging era of personalized medicine in advanced colorectal cancer
Authors:
Open Access
- 20 July 2022
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (8) , 1411-1425
Abstract
Colorectal cancer (CRC) is a genetically heterogeneous disease with its pathogenesis often driven by varying genetic or epigenetic alterations. This has led to a substantial number of patients developing chemoresistance and treatment failure, resulting in a high mortality rate for advanced disease. Deep molecular analysis has allowed for the discovery of key intestinal signaling pathways which impacts colonic epithelial cell fate, and the integral role of the tumor microenvironment on cancer growth and dissemination. Through transitioning pre‐clinical knowledge in research into clinical practice, many potential druggable targets within these pathways have been discovered in the hopes of overcoming the roadblocks encountered by conventional therapies. A personalized approach tailoring treatment according to the histopathological and molecular features of individual tumors can hopefully translate to better patient outcomes, and reduce the rate of recurrence in patients with advanced CRC. Herein, the latest understanding on the molecular science behind CRC tumorigenesis, and the potential treatment targets currently at the forefront of research are summarized.Keywords
Funding Information
- Wellcome Trust (206314/Z/17/Z)
This publication has 204 references indexed in Scilit:
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis InitiationCancer Cell, 2012
- Recurrent R-spondin fusions in colon cancerNature, 2012
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- The Tumor Microenvironment in Colorectal CarcinogenesisCancer Microenvironment, 2010
- TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyBritish Journal of Cancer, 2009
- Signaling cross-talk between TGF-β/BMP and other pathwaysCell Research, 2008
- The epidermal growth factor receptor family: Biology driving targeted therapeuticsCellular and Molecular Life Sciences, 2008
- A comprehensive pathway map of epidermal growth factor receptor signalingMolecular Systems Biology, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993